Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$6.88−0.14 (-1.99%)
Close on Nov 18, 2026Market cap $249.69MP/E –Yield –
Evommune free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Evommune's free cash flow for the twelve months ending Sep 30, 2026 was -$91.00M. For fiscal 2025 it was -$76.68M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$76.68M | – |
| FY2024 | Dec 31, 2024 | -$58.28M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$26.12M | – |
| Q2 FY2026 | Jun 30, 2026 | -$20.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.77M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.51M | – |
See a number that looks wrong?